论文部分内容阅读
目的探讨在ⅢA、ⅢB期非小细胞肺癌的同步放化治疗中,培美曲塞联合顺铂与多西他赛联合顺铂方案的治疗疗效及毒副反应情况。方法随机选取局部晚期非小细胞肺癌患者(ⅢA、ⅢB期)共82例作为实验对象,均为南京医科大学附属淮安第一医院2014-01-2015-10所接收,将其按照不同治疗方案均分成两组,就培美曲塞联合顺铂治疗(培美组n=41)与多西他赛联合顺铂治疗(多西他赛组n=41)的临床疗效及毒副反应进行对比探讨。结果从治疗效率方面分析,培美组和多西他赛组分别为:78.05%,75.61%,组间差异无统计学意义,P>0.05。从不良反应发生率方面分析,培美组和多西他赛组分别为24.40%,45.76%,组间差异有统计学意义,P<0.05。结论培美曲塞联合顺铂与多西他赛联合顺铂治疗肺癌的应用效果均比较好,疗效不差上下,但相比而言,培美曲塞联合顺铂治疗,患者的不良反应发生率比较低,治疗方案更理想,在临床有推广和普及的价值。
Objective To investigate the curative effect and toxicity of pemetrexed combined with cisplatin and docetaxel in combination with cisplatin in the concurrent radiotherapy of stage ⅢA and ⅢB non-small cell lung cancer. Methods A total of 82 patients with locally advanced non-small cell lung cancer (stage ⅢA, ⅢB) were randomly selected as the experimental subjects. All of them were received by Huaian First Affiliated Hospital of Nanjing Medical University from January 2014 to October 2015, and were treated according to different treatment plans The clinical efficacy and side effects of pemetrexed plus cisplatin (pemetrexed n = 41) and docetaxel plus cisplatin (docetaxel n = 41) were compared . Results From the aspect of treatment efficiency, there was no significant difference between the two groups (P> 0.05). From the analysis of the incidence of adverse reactions, pemetrexed group and docetaxel group were 24.40%, 45.76%, the difference between the groups was statistically significant, P <0.05. Conclusion Pemetrexed combined with cisplatin and docetaxel combined with cisplatin in the treatment of lung cancer are relatively good results, the effect is not bad from top to bottom, but in contrast, pemetrexed combined with cisplatin treatment, patients with adverse reactions The rate is relatively low, the treatment plan is more ideal and has the value of popularization and popularization in clinic.